![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » XENOMICS ANNOUNCES DEVELOPMENT OF TEST FOR THE GENETIC MARKER FOR ACUTE MYELOID LEUKEMIA (AML)
XENOMICS ANNOUNCES DEVELOPMENT OF TEST FOR THE GENETIC MARKER FOR ACUTE MYELOID LEUKEMIA (AML)
Xenomics, Inc., the source of next-generation medical DNA diagnostic tests, announced that it has developed a proprietary test for the detection of NPM gene mutations, a recently discovered genetic marker for Acute Myeloid Leukemia (AML). Xenomics already holds the exclusive license for the use of that marker. Yahoo News (http://biz.yahoo.com/prnews/060929/nyf016.html?.v=70)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct